FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 141 filers reported holding FIVE PRIME THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 5.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $645,000 | +125.5% | 17,112 | +1.8% | 0.27% | +128.6% |
Q4 2020 | $286,000 | -22.3% | 16,810 | -38.9% | 0.12% | -84.8% |
Q1 2019 | $368,000 | +26.0% | 27,492 | -12.5% | 0.78% | +1466.0% |
Q4 2018 | $292,000 | -21.7% | 31,427 | +17.2% | 0.05% | +28.2% |
Q3 2018 | $373,000 | -48.7% | 26,824 | -41.7% | 0.04% | -93.9% |
Q2 2018 | $727,000 | +17.1% | 46,007 | +27.3% | 0.64% | +19.3% |
Q1 2018 | $621,000 | +63.0% | 36,128 | +108.0% | 0.54% | +12.8% |
Q4 2017 | $381,000 | -15.1% | 17,371 | +58.4% | 0.48% | +683.6% |
Q3 2017 | $449,000 | +49.7% | 10,966 | +10.1% | 0.06% | +35.6% |
Q2 2017 | $300,000 | +47.8% | 9,963 | +77.0% | 0.04% | +25.0% |
Q1 2017 | $203,000 | -20.4% | 5,628 | +10.6% | 0.04% | -52.6% |
Q4 2016 | $255,000 | -16.7% | 5,088 | -12.8% | 0.08% | -48.6% |
Q3 2016 | $306,000 | +27.0% | 5,837 | 0.0% | 0.15% | -17.3% |
Q2 2016 | $241,000 | -6.2% | 5,837 | -7.7% | 0.18% | -49.4% |
Q1 2016 | $257,000 | – | 6,321 | – | 0.35% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Eventide Asset Management | 601,000 | $24,587,000 | 1.39% |
HealthCor Management, L.P. | 1,010,930 | $41,357,000 | 1.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 86,500 | $3,535,000 | 1.38% |
PURA VIDA INVESTMENTS, LLC | 75,000 | $3,068,000 | 0.90% |
BB BIOTECH AG | 777,500 | $31,808,000 | 0.88% |
AWM Investment Company, Inc. | 100,000 | $4,091,000 | 0.71% |
Granite Point Capital Management, L.P. | 50,000 | $2,046,000 | 0.43% |
Rock Springs Capital Management LP | 217,700 | $8,906,000 | 0.41% |
Crestline Management, LP | 50,919 | $2,083,000 | 0.29% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,432,700 | $99,522,000 | 0.24% |